Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?
Background: We aimed to compare the established metabolic response criteria PERCIST and EORTC for their applicability and predictive value in terms of clinical response assessment early after the initiation of lenvatinib therapy in patients with metastatic radioiodine-refractory (RAI) thyroid cancer...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/8/1868 |
| _version_ | 1797436581348376576 |
|---|---|
| author | Gundula Rendl Gregor Schweighofer-Zwink Stefan Sorko Hans-Jürgen Gallowitsch Wolfgang Hitzl Diana Reisinger Christian Pirich |
| author_facet | Gundula Rendl Gregor Schweighofer-Zwink Stefan Sorko Hans-Jürgen Gallowitsch Wolfgang Hitzl Diana Reisinger Christian Pirich |
| author_sort | Gundula Rendl |
| collection | DOAJ |
| description | Background: We aimed to compare the established metabolic response criteria PERCIST and EORTC for their applicability and predictive value in terms of clinical response assessment early after the initiation of lenvatinib therapy in patients with metastatic radioiodine-refractory (RAI) thyroid cancer (TC). Methods: In 25 patients treated with lenvatinib, baseline and 4-month follow-up F-18 FDG PET/CT images were analyzed using PERCIST 1.0, modified PERCIST (using SUVpeak or SUVmax) and EORTC criteria. Two groups were defined: disease control (DC) and progressive disease (PD), which were correlated with PFS and OS. Results: PERCIST, mPERCIST, PERCISTmax and EORTC could be applied in 80%, 80%, 88% and 100% of the patients based on the requirements of lesion assessment criteria, respectively. With PERCIST, mPERCIST, PERCISTmax and EORTC, the patients classified as DC and PD ranged from 65 to 68% and from 32 to 35%, respectively. Patients with DC exhibited a longer median PFS than patients with PD for EORTC (<i>p</i> < 0.014) and for PERCIST and mPERCIST (<i>p</i> = 0.037), respectively. Conclusion: EORTC and the different PERCIST criteria performed equally regarding the identification of patients with PD requiring treatment changes. However, the applicability of PERCIST 1.0 using SULpeak seems restricted due to the significant proportion of small tumor lesions. |
| first_indexed | 2024-03-09T11:04:42Z |
| format | Article |
| id | doaj.art-f2ec963243e849a1b1006daf31abe34c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T11:04:42Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f2ec963243e849a1b1006daf31abe34c2023-12-01T01:04:20ZengMDPI AGCancers2072-66942022-04-01148186810.3390/cancers14081868Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?Gundula Rendl0Gregor Schweighofer-Zwink1Stefan Sorko2Hans-Jürgen Gallowitsch3Wolfgang Hitzl4Diana Reisinger5Christian Pirich6Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Müllner Hauptstr. 48, 5020 Salzburg, AustriaDepartment of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Müllner Hauptstr. 48, 5020 Salzburg, AustriaDepartment of Nuclear Medicine and Endocrinology, PET/CT Centre, Klinikum Klagenfurt am Wörthersee, 9020 Klagenfurt, AustriaDepartment of Nuclear Medicine and Endocrinology, PET/CT Centre, Klinikum Klagenfurt am Wörthersee, 9020 Klagenfurt, AustriaResearch and Innovation Management, Biostatistics and Publication of Clinical Trial Studies, Paracelsus Medical University Salzburg, 5020 Salzburg, AustriaDepartment of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Müllner Hauptstr. 48, 5020 Salzburg, AustriaDepartment of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University Salzburg, Müllner Hauptstr. 48, 5020 Salzburg, AustriaBackground: We aimed to compare the established metabolic response criteria PERCIST and EORTC for their applicability and predictive value in terms of clinical response assessment early after the initiation of lenvatinib therapy in patients with metastatic radioiodine-refractory (RAI) thyroid cancer (TC). Methods: In 25 patients treated with lenvatinib, baseline and 4-month follow-up F-18 FDG PET/CT images were analyzed using PERCIST 1.0, modified PERCIST (using SUVpeak or SUVmax) and EORTC criteria. Two groups were defined: disease control (DC) and progressive disease (PD), which were correlated with PFS and OS. Results: PERCIST, mPERCIST, PERCISTmax and EORTC could be applied in 80%, 80%, 88% and 100% of the patients based on the requirements of lesion assessment criteria, respectively. With PERCIST, mPERCIST, PERCISTmax and EORTC, the patients classified as DC and PD ranged from 65 to 68% and from 32 to 35%, respectively. Patients with DC exhibited a longer median PFS than patients with PD for EORTC (<i>p</i> < 0.014) and for PERCIST and mPERCIST (<i>p</i> = 0.037), respectively. Conclusion: EORTC and the different PERCIST criteria performed equally regarding the identification of patients with PD requiring treatment changes. However, the applicability of PERCIST 1.0 using SULpeak seems restricted due to the significant proportion of small tumor lesions.https://www.mdpi.com/2072-6694/14/8/1868F-18 FDG PET/CTradioiodine-refractory differentiated thyroid cancertyrosine kinase inhibitorlenvatinibmetabolic response |
| spellingShingle | Gundula Rendl Gregor Schweighofer-Zwink Stefan Sorko Hans-Jürgen Gallowitsch Wolfgang Hitzl Diana Reisinger Christian Pirich Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable? Cancers F-18 FDG PET/CT radioiodine-refractory differentiated thyroid cancer tyrosine kinase inhibitor lenvatinib metabolic response |
| title | Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable? |
| title_full | Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable? |
| title_fullStr | Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable? |
| title_full_unstemmed | Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable? |
| title_short | Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable? |
| title_sort | assessment of treatment response to lenvatinib in thyroid cancer monitored by f 18 fdg pet ct using percist 1 0 modified percist and eortc criteria which one is most suitable |
| topic | F-18 FDG PET/CT radioiodine-refractory differentiated thyroid cancer tyrosine kinase inhibitor lenvatinib metabolic response |
| url | https://www.mdpi.com/2072-6694/14/8/1868 |
| work_keys_str_mv | AT gundularendl assessmentoftreatmentresponsetolenvatinibinthyroidcancermonitoredbyf18fdgpetctusingpercist10modifiedpercistandeortccriteriawhichoneismostsuitable AT gregorschweighoferzwink assessmentoftreatmentresponsetolenvatinibinthyroidcancermonitoredbyf18fdgpetctusingpercist10modifiedpercistandeortccriteriawhichoneismostsuitable AT stefansorko assessmentoftreatmentresponsetolenvatinibinthyroidcancermonitoredbyf18fdgpetctusingpercist10modifiedpercistandeortccriteriawhichoneismostsuitable AT hansjurgengallowitsch assessmentoftreatmentresponsetolenvatinibinthyroidcancermonitoredbyf18fdgpetctusingpercist10modifiedpercistandeortccriteriawhichoneismostsuitable AT wolfganghitzl assessmentoftreatmentresponsetolenvatinibinthyroidcancermonitoredbyf18fdgpetctusingpercist10modifiedpercistandeortccriteriawhichoneismostsuitable AT dianareisinger assessmentoftreatmentresponsetolenvatinibinthyroidcancermonitoredbyf18fdgpetctusingpercist10modifiedpercistandeortccriteriawhichoneismostsuitable AT christianpirich assessmentoftreatmentresponsetolenvatinibinthyroidcancermonitoredbyf18fdgpetctusingpercist10modifiedpercistandeortccriteriawhichoneismostsuitable |